By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Nilesh Shah joins Illumina as Head of Region, AMEA
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > News > Nilesh Shah joins Illumina as Head of Region, AMEA
Nilesh Shah joins Illumina as Head of Region, AMEA
News

Nilesh Shah joins Illumina as Head of Region, AMEA

Last updated: 19/08/2025 12:37 PM
Published: 19/08/2025
Share
SHARE

SINGAPORE, Aug. 19, 2025 /PRNewswire/ — Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced today the appointment of Nilesh Shah as Head of Region, AMEA, effective immediately.

- Advertisement -

Nilesh brings over 25 years of leadership experience in the medical technology and life sciences industries, having held senior roles at Johnson & Johnson, GE Healthcare and most recently, West Pharmaceutical Services. At West, he served as Vice President & General Manager, Emerging Markets, where he led commercial, operational, and manufacturing strategies spanning Asia-Pacific and Latin America. During his tenure, he drove regional transformation, enhanced customer engagement, and delivered strong growth through a more aligned and agile operating model.

- Advertisement -

“We are excited to welcome Nilesh to Illumina. His deep expertise in healthcare and global organizations is a valuable addition to the AMEA team and our broader commercial organization,” said Everett Cunningham, Chief Commercial Officer at Illumina. “AMEA represents one of the most dynamic and fast-growing regions in the world, with significant opportunities to expand access to genomic technologies. We look forward to seeing how Nilesh’s leadership will help shape the next chapter of growth and impact across the region.”

- Advertisement -

“Genomics and multi-omics are rapidly transforming precision medicine and reshaping healthcare across every stage of life,” Nilesh stated. “I am honored to join Illumina as Head of AMEA. Together, we will work with our customers, partners, and the entire ecosystem to harness the full potential of these technologies – not just advancing regional health outcomes, but improving health for communities worldwide.”

- Advertisement -

Nilesh will be based in Singapore. He succeeds Bas Verhoef, interim Head of Region, AMEA. Verhoef will continue to serve as Head of Region for Europe. 

- Advertisement -

About Illumina

- Advertisement -

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2753266/Nilesh_photo_high_res.jpg
Logo – https://mma.prnewswire.com/media/2753262/Illumina_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/nilesh-shah-joins-illumina-as-head-of-region-amea-302533189.html

- Advertisement -
Bybit Alpha Celebrates Luck and Mastery with up to 8,000 USDT in Rewards for Top Winners
Bybit Card Honored as “the Best Performing Crypto Card” by Mastercard at EDGE 2025
Former Google Exec Outlines the High-Stakes Battle Behind Google Reviews on Maury Blackman’s Great Minds Think Data
Axtria and Kedaara Capital Announce Strategic $240 Million Investment and Employee Share Buy Back Program
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
TAGGED:ameaheadilluminajoinsnewsnileshregionshah
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting
Health

Multiple Myeloma Research Foundation (MMRF) Announces New Data from Flagship Research Initiatives at the 22nd International Myeloma Society Annual Meeting

GlobeNews Wire
GlobeNews Wire
21/09/2025
GameChange BOS Surpasses Orders for 190 Transformers as New Manufacturing Facility Ramps Up
J.S. Held Experts Contribute to the International Valuation Standards Council Report on Intangible Assets in ASEAN Capital Markets
Fenova uPVC Door & Window Systems Recognized by Forbes India DGEMS as a SELECT 200 Company with Global Business Potential
Ethereum Trades Above $4.6K as Bybit Releases 10-Year Outlook Report
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?